Spinogenix Announces World Health Organization Approval of "Codabakalner" as International Nonproprietary Name for SPG601

RegulatoryCodabakalnerPositive

AI Analysis

Summary

Spinogenix announced WHO approval of the International Nonproprietary Name (INN) 'Codabakalner' for its investigational therapy SPG601, a first-in-class candidate entering Phase 2b/3 development for Fragile X Syndrome.

Clinical Trial Data

Phase

Phase 2b/3

Outcome Details

WHO approved Codabakalner as International Nonproprietary Name (INN) for SPG601

Importance:4/10

Sentiment:

0.60

rare_diseasefragile_x_syndromefirst_in_classregulatory_approvalINN_approval

Related Companies

$ISCO $HIT $TRAX $WHEN

Read the original article

Published by PR Newswire Clinical Trials on July 16, 2026 12:30 PM

Read Original